Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Worth Financial Advisory Group LLC

Worth Financial Advisory Group LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 283.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,603 shares of the medical research company's stock after purchasing an additional 1,185 shares during the quarter. Worth Financial Advisory Group LLC's holdings in Thermo Fisher Scientific were worth $798,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Cassaday & Co Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 0.9% during the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after buying an additional 20 shares during the last quarter. Callan Capital LLC lifted its holdings in Thermo Fisher Scientific by 2.7% during the 4th quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock worth $402,000 after buying an additional 20 shares during the last quarter. One Charles Private Wealth Services LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after buying an additional 20 shares during the last quarter. Finally, Holderness Investments Co. lifted its holdings in Thermo Fisher Scientific by 1.7% during the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock worth $664,000 after buying an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded up $4.75 during trading hours on Friday, hitting $397.31. The company's stock had a trading volume of 3,760,318 shares, compared to its average volume of 1,942,727. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $149.98 billion, a PE ratio of 23.30, a PEG ratio of 2.10 and a beta of 0.78. The company has a 50-day simple moving average of $412.62 and a 200 day simple moving average of $487.56.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm earned $5.11 EPS. The firm's revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Analysts Set New Price Targets

A number of research firms have commented on TMO. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Royal Bank Of Canada cut their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, UBS Group cut their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $605.30.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.